Vivo Capital, a global healthcare investment firm that has backed Chinese companies including medical tech platform WuXi AppTec, has held the first closing of a new RMB-denominated fund at 4 billion yuan ($600 million) with a total fundraising target of about 10 billion yuan ($1.5 billion).
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
